Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation

Today, the researchers continue the search for the most optimal regimens of drug therapy for metastatic colorectal cancer (mCRC) which are supposed to increase progression-free survival (PFS) and overall survival (OS), improve patient quality of life. Due to significant progress in chemotherapy (CT)...

Celý popis

Podrobná bibliografie

Hlavní autoři:	A. D. Darenskaya, N. V. Dobrova, B. M. Medvedeva
Médium:	Artigo
Jazyk:	Russo
Vydáno:	Remedium Group LLC 2018-11-01
Edice:	Медицинский совет
Témata:	metastatic colorectal cancer (mcrc) targeted therapy epidermal growth factor receptor (egfr) monoclonal antibody (mab) cetuximab chemotherapy (ct) irinotecan oxaliplatin fluoropyrimidines
On-line přístup:	https://www.med-sovet.pro/jour/article/view/2744
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!